Beauty Health (SKIN)
(Real Time Quote from BATS)
$1.57 USD
-0.07 (-4.27%)
Updated Sep 18, 2024 10:32 AM ET
4-Sell of 5 4
D Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
SKIN 1.57 -0.07(-4.27%)
Will SKIN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SKIN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SKIN
Compared to Estimates, Beauty Health (SKIN) Q2 Earnings: A Look at Key Metrics
ModivCare (MODV) Reports Q2 Loss, Misses Revenue Estimates
SKIN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
McKesson (MCK) Q4 Earnings and Revenues Lag Estimates
Other News for SKIN
Beauty Health price target lowered by $1.80 at TD Cowen, here's why
Hold Rating on Beauty Health Amidst Sales Decline and Prospects for Recovery
Beauty Health price target lowered by 75c at Canaccord, here's why
Expert Outlook: Beauty Health Through The Eyes Of 4 Analysts
The Beauty Health Company Q2 2024 Earnings: Will It Ever Be Profitable?